University of Birmingham researchers have discovered that muscle loss in end-stage liver disease follows distinct biological pathways depending on what caused the liver damage in the first place—a finding that could transform how doctors treat one of the most debilitating complications of severe liver disease. Sarcopenia, the wasting of skeletal muscle mass and strength, affects roughly 1 in 3 people who develop end-stage liver disease, nearly doubling their risk of death while leaving them vulnerable to falls and serious infections. Yet until now, treatment has been one-size-fits-all, with no approved medications available at all.
The research, published in the Journal of Cachexia, Sarcopenia and Muscle, analyzed muscle tissue taken directly from patients with end-stage liver disease and compared it with tissue from healthy individuals. Using transcriptomics—a technique that reveals which genes are switched on or off—the team identified more than 600 genes that behaved differently in diseased muscle. When they grouped patients by the underlying cause of their liver disease—alcohol-related, metabolic, or immune-associated—each group displayed a distinct molecular signature in their muscle tissue. This suggests that sarcopenia in liver disease is not one condition but a collection of related disorders driven by different biological mechanisms.
To understand what might be driving these changes, the researchers measured 60 different proteins in patients' blood, including inflammatory signals and growth factors. They then exposed human muscle cells in the laboratory to blood plasma from liver disease patients. The plasma triggered changes that mirrored those seen in actual patient tissue, including accelerated protein breakdown. Three proteins emerged as potential drivers: IL-1α, GDF-15, and HGF.
The pattern proved telling. GDF-15, a stress-related protein, was elevated across all disease subtypes. IL-1α was specifically elevated in patients with immune-associated liver disease, while HGF appeared elevated in those with metabolic and alcohol-related liver disease. When researchers treated human muscle cells with these three proteins at levels matching those in patients, the cells became thinner, showed impaired growth, and displayed disrupted energy metabolism—the hallmarks of muscle wasting.
"By mapping molecular changes directly in patient muscle tissue, we've been able to show that different liver diseases leave different signatures in muscle," said Professor Simon Jones, senior author and lead for the NIHR Biomedical Research Center's Sarcopenia and Multimorbidity research theme. "That's a crucial step towards moving away from one-size-fits-all approaches and towards treatments tailored to the patient's underlying disease."
The implications are practical and immediate. Some of the proteins identified are already being targeted by drugs developed for other conditions, raising the possibility that existing treatments could be repurposed to protect muscle health in liver disease patients, potentially working alongside exercise and nutritional support. First author Thomas Nicholson, a doctoral researcher at Birmingham, emphasized that identifying what drives sarcopenia in an individual patient may be key to developing truly effective interventions.
For millions living with severe liver disease, this research offers something long absent: the prospect of personalized medicine that matches treatment to biology, rather than hoping a single approach works for everyone.